Saatci, O. Et Al. 2024. Targeting LINC00152 activates cAMP/Ca²⁺/ferroptosis axis and overcomes tamoxifen resistance in ER plus breast cancer. CELL DEATH & DISEASE , no.6 .

Saatci, O., Alam, R., Huynh-Dam, K., Isik, A., ÜNER, M., BELDER, N., ... Ersan, P. G.(2024). Targeting LINC00152 activates cAMP/Ca²⁺/ferroptosis axis and overcomes tamoxifen resistance in ER plus breast cancer. CELL DEATH & DISEASE , no.6.

Saatci, Ozge Et Al. "Targeting LINC00152 activates cAMP/Ca²⁺/ferroptosis axis and overcomes tamoxifen resistance in ER plus breast cancer," CELL DEATH & DISEASE , no.6, 2024

Saatci, Ozge Et Al. "Targeting LINC00152 activates cAMP/Ca²⁺/ferroptosis axis and overcomes tamoxifen resistance in ER plus breast cancer." CELL DEATH & DISEASE , no.6, 2024

Saatci, O. Et Al. (2024) . "Targeting LINC00152 activates cAMP/Ca²⁺/ferroptosis axis and overcomes tamoxifen resistance in ER plus breast cancer." CELL DEATH & DISEASE , no.6.

@article{article, author={Ozge Saatci Et Al. }, title={Targeting LINC00152 activates cAMP/Ca²⁺/ferroptosis axis and overcomes tamoxifen resistance in ER plus breast cancer}, journal={CELL DEATH & DISEASE}, year=2024}